Results 1 to 10 of about 3,475,545 (379)

Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer’s disease

Frontiers in Aging Neuroscience, 2023
BackgroundSeveral blood-based biomarkers are promising to be used in the diagnosis of Alzheimer’s disease (AD) including Aβ42/40, p-tau181, and neurofilament light (NfL). The kidney is associated with the clearance of proteins.
Bin Zhang, Cheng Zhang, YuYe Wang, LeiAn Chen, YaNan Qiao, Yu Wang, DanTao Peng, for the Alzheimer’s Disease Neuroimaging Initiative   +7 more
doaj   +2 more sources

Accurate and robust prediction of Amyloid-β brain deposition from plasma biomarkers and clinical information using machine learning [PDF]

Frontiers in Aging Neuroscience
BackgroundAlzheimer's disease (AD) greatly affects the daily functioning and life quality of patients and is prevalent in the elderly population. Amyloid-β (Aβ) accumulation in the brain is the main hallmark of AD pathophysiology.
Jiayuan Xu, Andrew J. Doig, Sofia Michopoulou, Sofia Michopoulou, Petroula Proitsi, Petroula Proitsi, Fumie Costen, The Alzheimer's disease neuroimaging initiative   +7 more
doaj   +2 more sources

Plasma Metabolomic Profiling Reveals Preliminary Biomarkers of Pork Quality Based on pH Value

Foods, 2022
This study aimed to identify biomarkers for pork quality evaluation. Firstly, the correlation between indicators of pork quality evaluation was investigated. The pH of pork meat at 45 min post slaughter showed a significant negative correlation with meat
Linyuan Shen, Jianfeng Ma, Haodi Zhou, Lei Chen, Jie Tang, Kaige Zhang, Ye Zhao, Lili Niu, Shunhua Zhang, Anan Jiang, Jinyong Wang, Zongyi Guo, Xuewei Li, Yiwu Chen, Mailin Gan, Li Zhu   +15 more
doaj   +1 more source

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

JAMA Neurology, 2023
Key Points Question Can plasma biomarkers predict cognitive decline in preclinical Alzheimer disease (AD)? Findings In this prognostic study of data from 2 preclinical AD cohort studies including 171 cognitively unimpaired individuals with cerebrospinal ...
N. Mattsson-Carlgren, Gemma Salvadó, N. Ashton, P. Tideman, E. Stomrud, H. Zetterberg, R. Ossenkoppele, T. Betthauser, K. Cody, E. Jonaitis, Rebecca E Langhough, S. Palmqvist, K. Blennow, S. Janelidze, Sterling C. Johnson, O. Hansson   +15 more
semanticscholar   +1 more source

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

EMBO Molecular Medicine, 2023
Several promising plasma biomarkers for Alzheimer's disease have been recently developed, but their neuropathological correlates have not yet been fully determined. To investigate and compare independent associations between multiple plasma biomarkers (p‐
Gemma Salvadó, R. Ossenkoppele, N. Ashton, T. Beach, G. Serrano, E. Reiman, H. Zetterberg, N. Mattsson-Carlgren, S. Janelidze, K. Blennow, O. Hansson   +10 more
semanticscholar   +1 more source

Predicting amyloid PET and tau PET stages with plasma biomarkers

Brain : a journal of neurology, 2023
Staging the severity of Alzheimer’s disease pathology using biomarkers is useful for therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face validity; however, this would be more practical with plasma biomarkers.
C. Jack, H. Wiste, A. Algeciras-Schimnich, D. Figdore, C. Schwarz, V. Lowe, V. Ramanan, P. Vemuri, M. Mielke, D. Knopman, J. Graff‐Radford, B. Boeve, K. Kantarci, P. Cogswell, M. Senjem, J. Gunter, T. Therneau, R. Petersen   +17 more
semanticscholar   +1 more source

Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice

Journal of Alzheimer's disease reports, 2023
Recently, low-sensitive plasma assays have been replaced by new ultra-sensitive assays such as single molecule enzyme-linked immunosorbent assay (Simoa), the Mesoscale Discovery (MSD) platform, and immunoprecipitation-mass spectrometry (IP-MS) with ...
M. Pais, O. Forlenza, B. Diniz
semanticscholar   +1 more source

The dynamics of plasma biomarkers across the Alzheimer’s continuum

Alzheimer's Research & Therapy, 2023
Background Failures in drug trials strengthen the necessity to further determine the neuropathological events during the development of Alzheimer’s disease (AD). We sought to investigate the dynamic changes and performance of plasma biomarkers across the
Yu Guo, Xue‐Ning Shen, Hui-Fu Wang, Shi‐Dong Chen, Ya-Ru Zhang, Shu-Fen Chen, Mei Cui, W. Cheng, Qiang-Li Dong, Tao Ma, Jin Yu   +10 more
semanticscholar   +1 more source

Plasma biomarkers predict Alzheimer’s disease before clinical onset in Chinese cohorts

Nature Communications, 2023
Plasma amyloid-β (Aβ)42, phosphorylated tau (p-tau)181, and neurofilament light chain (NfL) are promising biomarkers of Alzheimer’s disease (AD). However, whether these biomarkers can predict AD in Chinese populations is yet to be fully explored.
Hui-qiang Cai, Yana Pang, Xiaofeng Fu, Ziye Ren, Longfei Jia   +4 more
semanticscholar   +1 more source

Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic

Journal of Neurology Neurosurgery & Psychiatry, 2023
Background The key Alzheimer’s disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid Aβ42 and p-tau181), or poorly ...
D. Altomare, Sara Stampacchia, F. Ribaldi, Szymon Tomczyk, Claire Chevalier, G. Poulain, Saina Asadi, Bianca Bancila, M. Marizzoni, Marta Martins, Aurélien Lathuilière, M. Scheffler, N. Ashton, H. Zetterberg, K. Blennow, Ilse Kern, M. Frias, V. Garibotto, G. Frisoni   +18 more
semanticscholar   +1 more source